In the general news, European courts ruled that Google must honor request by individuals to delete links about them that are embarrassing, which a s first for the “right to forget” movement. In the U.S., the 9/11 memorial in New York finally opened.
On the data front, the CDC issued a report about toddlers being inappropriately prescribed ADHD stimulant drugs. ASCO cancer drugs dominated the news, with Roche, BMY, and MRK immunotherapy drugs, this year again, being the headliners. In diabetes, Isis’ (ISIS) drug ISIS-GCGRRx met endpoints, as did LLY’s drug peglispro. Lastly, Tesaro’s (TSRO) rolapitant drug for chemotherapy-induced nausea met endpoints.
From the FDA, as expected, Novartis’ (NVS) serelaxin was rejected, despite it being a “Breakthrough” category. This indicates that not all “Breakthrough” drugs are sure bets for approval.